Explore Dihexa dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Dihexa (PNB0408) is a potent angiotensin IV-derived hexapeptide that potentiates hepatocyte growth factor (HGF) signaling through the MET receptor, studied for its striking effects on spatial memory and cognitive performance in preclinical models. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their Dihexa reconstitution protocol.
Dihexa (also known as PNB0408 or N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a potent nootropic hexapeptide derived from angiotensin IV, developed by the Joseph Harding and John Wright laboratories at Washington State University (WSU). The molecule was characterized in the landmark McCoy et al. (2013) Journal of Pharmacology and Experimental Therapeutics paper, which reported that Dihexa potentiates the binding of hepatocyte growth factor (HGF) to its receptor MET (c-Met), amplifying HGF/MET signaling in hippocampal neurons and producing robust improvements in spatial memory in aged rat models of cognitive decline. The potency reported was extraordinary — McCoy et al.
Dihexa is a small peptide derivative of angiotensin IV, most often sourced for cognitive and neuroprotection research. It was engineered to survive oral dosing and cross the blood-brain barrier. It is a research compound with no human trials, usually supplied as a powder for oral or solution use.
Dihexa is proposed to act as a positive allosteric modulator of the hepatocyte growth factor (HGF) / c-Met receptor system in the central nervous system, potentiating HGF-driven synaptogenesis and dendritic spine formation in hippocampal pyramidal neurons. It does not bind the AT1 or AT2 angiotensin receptors at meaningful concentrations.
Pre-clinical work has reported that oral and intraperitoneal Dihexa restored Morris-water-maze performance in scopolamine-impaired and aged rats and increased dendritic-spine density in cultured hippocampal neurons. No registered clinical trial in humans has been conducted; the molecule remains a research-stage compound discussed primarily in the nootropic community.
Dihexa has a reported half-life of ~few hours (estimated), and the dose intervals researchers model most often fall around once daily (oral). Short-acting in the blood, so daily dosing works as a fresh pulse with little buildup. Its downstream effects are thought to persist longer than the blood level. It is catalogued under Memory Peptides on WPA.
31 Dihexa reconstitution calculations have been logged by the WPA community. The most common dose entered is 2.5mg (6 calculations). The median dose across all sessions is 1mg. The most common bacteriostatic water volume is 3mL. The most popular vial size is 10mg (25 sessions). The most common dosing frequency is daily (7x/week) (5 logged protocols), followed by 4x/week (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.